Table 1.
Selected allogeneic HSCT clinical trials in RCC patients (in chronological order).
| Authors | No of patients | TRM (%) | Response rate % (CR/PR/MR) |
Response onset day (median) |
|---|---|---|---|---|
| Childs et al13 | 19 | 12% | 53% (3/7) | 129 |
| Bregni et al78 | 7 | 14% | 57% (0/4) | 117 |
| Pedrazzoli et al79 | 7 | 29% | 0% (0/0) | N/A |
| Rini et al80 | 12 | 33% | 33% (0/4) | 180 |
| Hentschke et al19 | 10 | 30% | 30% (0/3) | NR |
| Ueno et al81 | 15 | 33% | 47% (1/2/4) | NR |
| Artz et al82 | 18 | 28% | 22% (0/4) | 182 |
| Barkholt et al14 | 124 | 16% | 29% (4/24) | 150 |
| Takahashi et al32* | 74 | 11% | 39% (7/22) | 133 |
A follow-up study of Childs et al.13
TRM, transplant-related mortality; CR, complete response; PR, partial response; MR, marginal response; NR, not reported.